Virus | Jotup

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Retrieved on:

Friday, March 15, 2024

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.

Key Points:

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.
“Calidi continues to make great progress across our development programs while continuing to innovate and expand our industry-leading position in cell-based immunotherapies,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
Publicly announced novel systemic enveloped oncolytic virotherapy program, RTNova (CLD-400), targeting advanced solid tumors, including advanced metastatic disease.
General and administrative expenses were $16.0 million for the year ended December 31, 2023, compared to $15.9 million for the year ended December 31, 2022, respectively.

Nintendo Celebrates MAR10 Day With Games, Movie News and a Variety of Mario-Themed Activities

Retrieved on:

Monday, March 11, 2024

View the full release here: https://www.businesswire.com/news/home/20240311148081/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240311148081/en/
Paper Mario: The Thousand-Year Door arrives on the Nintendo Switch family of systems on May 23.
The witty and whimsical RPG arrives on the Nintendo Switch system twenty years after its original debut on Nintendo GameCube.
* In honor of MAR10 Day, Nintendo is offering twice the fun with the Nintendo Switch Online 14-Day Free Trial Membership (typically 7 days), available now through March 17 on My Nintendo .
Watch the Super Mario Bros. Movie and Check Out the Companion Digital Guidebook – What better way to celebrate MAR10 Day than to watch The Super Mario Bros. Movie?

Edgescan Releases 2024 Vulnerability Statistics Report

Retrieved on:

Friday, April 5, 2024

Cross-site scripting, Organization, Database, Risk, SQL injection, Virus, Identity theft

NEW YORK, April 5, 2024 /PRNewswire/ -- Edgescan, a leading international provider of risk-based vulnerability management and penetration testing, released its much anticipated annual 'Vulnerability Statistics Report'. This comprehensive data set sheds light on the critical IT vulnerabilities that continue to pose a significant threat to organizations worldwide.

Key Points:

NEW YORK, April 5, 2024 /PRNewswire/ -- Edgescan, a leading international provider of risk-based vulnerability management and penetration testing, released its much anticipated annual 'Vulnerability Statistics Report'.
Additional findings from the 2023 report include:
SQL Injection remains the foremost critical vulnerability in web applications, accounting for 19.47% of vulnerabilities detected and requiring 15 days to remedy.
Eoin Keary, Founder & CEO of Edgescan, "Our Vulnerability Statistics Report serves as a wake-up call to organizations across industries and around the world.
The 2024 Vulnerability Statistics Report is Edgescan's ninth edition.

Datasea Enters into a Sales Agreement for its Acoustic Products Bringing its Evolutionary Technology to Market in a Strategic Milestone to Develop Rapid Online Sales

Retrieved on:

Thursday, April 4, 2024

Kirby: Planet Robobot, PDD, Growth, Agreement, RMB, Partnership, COVID-19, Taobao, Sterilization, Sale, Bacteria, Virus, Marketing, Shenzhen, Digital technology, Intelligence, Online shopping

The signing of this Agreement signifies a new milestone for Datasea in promoting the domestic and international sales of its acoustic high tech products and it is expected to be a key driver of the Company's future revenue growth.

Key Points:

The signing of this Agreement signifies a new milestone for Datasea in promoting the domestic and international sales of its acoustic high tech products and it is expected to be a key driver of the Company's future revenue growth.
Zhixin Liu, CEO of Datasea, commented, "We are delighted to have signed this Agreement with Xiaoranfang Marketing.
This marks a significant milestone in advancing the market promotion and sales of our leading-edge acoustic high tech products.
We are confident that our experience with digital sales promotion and online sales channels, with our large customer base, will promote sales of Datasea's products and achieve a win-win situation."

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

Retrieved on:

Thursday, March 28, 2024

Conference, Virus

HOUSTON, March 28, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Walter Klemp, President and Chief Executive Officer of Moleculin will present at the MedInvest Biotech & Pharma Investor Conference behind held in New York City, NY on Thursday, April 4, 2024 at 4:10 PM ET.

Key Points:

HOUSTON, March 28, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Walter Klemp, President and Chief Executive Officer of Moleculin will present at the MedInvest Biotech & Pharma Investor Conference behind held in New York City, NY on Thursday, April 4, 2024 at 4:10 PM ET.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
For more information about the event, please visit the conference website .

Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows

Retrieved on:

Thursday, March 28, 2024

SAN ANTONIO, March 27, 2024 /PRNewswire-PRWeb/ -- Autism and attention deficit hyperactivity disorder (ADHD) may be preventable if parents avoid toxic exposures and adopt interventions such as environmental house calls, according to a published study led by researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio).

Key Points:

The findings build on a 2015 study by UT Health San Antonio that first linked chemical intolerance in patients with the risk of their children developing autism and ADHD.
"Up to now, most interventions have been behavioral or medical, after a child is diagnosed."
Still, they wrote, "The implications of this study, if confirmed, could be significant for preventive measures and early intervention strategies in families with parental chemical intolerance.
And the prevalence of ADHD has risen to one in eight children, also according to the CDC.

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

Retrieved on:

Wednesday, March 27, 2024

Virtual, Virus, Management

HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET.

Key Points:

Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28th at 12:00 PM ET
HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET.
As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide a corporate overview, business outlook, and discuss the Moleculin opportunity.
A live video webcast of the event will be available on the Events page under the Investors section of the Company's website ( moleculin.com ).
A webcast replay will be available two hours following the live event and will be accessible for 90 days.

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

Retrieved on:

Wednesday, March 27, 2024

AML, Monroe Dunaway Anderson, CRC, Patient, Acute myeloid leukemia, Virus, University, United States patent law, Clinical trial, FDA, STS, Pharmaceutical industry

HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,951,118 titled, "Preparation of Preliposomal Annamycin Lyophilizate" (the '118 patent') to be issued on April 9, 2024 to Moleculin and The University of Texas System Board of Regents.

Key Points:

Moleculin's novel candidate for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets) uses a unique lipid-based delivery technology.
In addition to the expected '118 patent, Moleculin has additional patent applications pending in the U.S. and in major jurisdictions worldwide.
Issuance of this patent underscores the importance and proprietary nature of the innovation that makes this next generation anthracycline possible."
Annamycin is Moleculin's next-generation anthracycline, initially expected to fulfill a significant unmet need for the 2nd line treatment of relapsed or refractory AML patients.

AV-Comparatives: Celebrating 20 Years of Excellence in Cybersecurity Testing

Retrieved on:

Wednesday, March 20, 2024

EDR, Computer science, University, European, XDR, Virus, EPP, Risk management

INNSBRUCK, Austria, March 20, 2024 /PRNewswire/ -- AV-Comparatives, an independent organisation that conducts comprehensive testing and evaluations of antivirus and security software, is celebrating its 20th anniversary.

Key Points:

INNSBRUCK, Austria, March 20, 2024 /PRNewswire/ -- AV-Comparatives, an independent organisation that conducts comprehensive testing and evaluations of antivirus and security software, is celebrating its 20th anniversary.
Founded in 2004, AV-Comparatives has been active in the cybersecurity industry for over two decades, providing valuable insights into the effectiveness of various security solutions.
Read the full details here: https://www.av-comparatives.org/reports/anniversary-report-2004-2023-20-...
The story of AV-Comparatives began in 1993 when Andreas Clementi was hit by a computer virus.
AV-Comparatives remains steadfast in its mission to foster a safer digital world through rigorous testing, insightful analysis, and unwavering dedication to excellence.

AV-Comparatives: Celebrating 20 Years of Excellence in Cybersecurity Testing

Retrieved on:

Wednesday, March 20, 2024

EDR, Computer science, University, European, XDR, Virus, EPP, Risk management

INNSBRUCK, Austria, March 20, 2024 /PRNewswire/ -- AV-Comparatives, an independent organisation that conducts comprehensive testing and evaluations of antivirus and security software, is celebrating its 20th anniversary.

Key Points:

INNSBRUCK, Austria, March 20, 2024 /PRNewswire/ -- AV-Comparatives, an independent organisation that conducts comprehensive testing and evaluations of antivirus and security software, is celebrating its 20th anniversary.
Founded in 2004, AV-Comparatives has been active in the cybersecurity industry for over two decades, providing valuable insights into the effectiveness of various security solutions.
Read the full details here: https://www.av-comparatives.org/reports/anniversary-report-2004-2023-20-...
The story of AV-Comparatives began in 1993 when Andreas Clementi was hit by a computer virus.
AV-Comparatives remains steadfast in its mission to foster a safer digital world through rigorous testing, insightful analysis, and unwavering dedication to excellence.